Gut bacteria boost: could a probiotic supercharge cancer treatment?
NCT ID NCT05122546
Summary
This early-stage study is testing if adding a probiotic called CBM588 to standard cancer drugs (cabozantinib and nivolumab) can help patients with advanced kidney cancer. The probiotic aims to improve the mix of 'good' bacteria in the gut, which might help the body's immune system fight the cancer better. Researchers will measure changes in gut bacteria and see if the combination is safe and more effective than the drugs alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.